PD Frontline – Neuroprogressive and Dementia Network

PD Frontline: genetic testing provision to facilitate clinical trial referral for people with Parkinson’s

PD Frontline is a remote study that offers online genetic testing for individuals with Parkinson’s disease, allowing them to be referred to relevant clinical trials and research studies if they wish. Approximately 20% of Parkinson’s cases are linked to genetic variations. By studying genes, researchers aim to develop targeted treatments that address specific biochemical pathways. To test these treatments, study teams need to identify individuals with these genetic variations who can participate in suitable clinical trials.

This study will enable referral into a new clinical trial, titled ‘Ambroxol to Slow Progression in Parkinson’s’ (ASPro-PD). This large-scale phase 3 trial aims to determine whether ambroxol can slow or halt the progression of Parkinson’s disease and is set to commence shortly. Information on ASPro-PD can be found here.

This study is open to recruitment

To find out more about this research study, please contact:
loth.sdcrn@nhs.scot
0131 537 3804

Key Staff

NDN Principle Investigator : Dr David Breen

This study is looking at patients with Parkinson’s Disease.

CONTACT INFORMATION

Neuroprogressive & Dementia Research Network Office

Old Pharmacy Building
Western General Hospital
Edinburgh
EH4 2XU

Email: loth.sdcrn@nhs.scot

Telephone: 0131 537 3804

ABOUT US

The NRS Neuroprogressive Disease and Dementia Network team in NHS Lothian conduct commercial and investigator led studies for: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Motor Neurone Disease, dementia with Lewy bodies, Progressive Supranuclear Palsy and Multiple System Atrophy.